Literature DB >> 15638748

The importance of guidelines in the development and application of probiotics.

Gregor Reid1.   

Abstract

Probiotics, defined as "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" have many attributes including the lack of adverse side effects associated with their use. While probiotics have proven benefits, the optimism associated with their use is counterbalanced by the fact that many so-called "probiotic" products are unreliable in content and unproven clinically. Therefore much remains to be done to gain the acceptance of the broader medical community. Recognition of the obvious product inequality and the lack of any regulatory guidelines lead to the development of Operating Standards in 2002 (FAO/WHO), that would ensure product safety, reliability and a level playing field for all companies producing probiotic products. The guidelines constitute a set of parameters required for a product/strain to be termed "probiotic" and also the clinically relevant steps to be followed to move probiotics closer to being embraced by the medical community. These include i) implementation of Guidelines for use of probiotics; ii) phase I, II and III clinical trials to prove health benefits that are as good as or better than standard prevention or treatments for a particular condition or disease; iii) Good Manufacturing Practice and production of high quality products; iv) studies to identify mechanism of action in vivo; v) informative/ precise labelling; vi) development of probiotic organisms that can carry vaccines to hosts and/or anti- viral probiotics; vii) expansion of proven strains to benefit the oral cavity, nasopharynx, respiratory tract, stomach, vagina, bladder and skin as well as for cancer, allergies and recovery from surgery/ injury.

Entities:  

Mesh:

Year:  2005        PMID: 15638748     DOI: 10.2174/1381612053382395

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  49 in total

1.  Probiotic Therapies for IBD.

Authors:  Richard N Fedorak
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  Microbiota restoration: natural and supplemented recovery of human microbial communities.

Authors:  Gregor Reid; Jessica A Younes; Henny C Van der Mei; Gregory B Gloor; Rob Knight; Henk J Busscher
Journal:  Nat Rev Microbiol       Date:  2010-11-29       Impact factor: 60.633

3.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

4.  Lactobacillus rhamnosus GG culture supernatant ameliorates acute alcohol-induced intestinal permeability and liver injury.

Authors:  Yuhua Wang; Yanlong Liu; Anju Sidhu; Zhenhua Ma; Craig McClain; Wenke Feng
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-04-26       Impact factor: 4.052

5.  Probiotics prophylaxis in children with persistent primary vesicoureteral reflux.

Authors:  Seung Joo Lee; Yoon Hee Shim; Su Jin Cho; Jung Won Lee
Journal:  Pediatr Nephrol       Date:  2007-05-26       Impact factor: 3.714

6.  Probiotics to prevent the need for, and augment the use of, antibiotics.

Authors:  Gregor Reid
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

7.  Probiotics research in Galleria mellonella.

Authors:  Gerwald Köhler
Journal:  Virulence       Date:  2015       Impact factor: 5.882

8.  Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.

Authors:  Takashi Asahara; Akira Takahashi; Norikatsu Yuki; Rumi Kaji; Takuya Takahashi; Koji Nomoto
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

9.  Protective mechanisms of respiratory tract Streptococci against Streptococcus pyogenes biofilm formation and epithelial cell infection.

Authors:  Tomas Fiedler; Catur Riani; Dirk Koczan; Kerstin Standar; Bernd Kreikemeyer; Andreas Podbielski
Journal:  Appl Environ Microbiol       Date:  2012-12-14       Impact factor: 4.792

Review 10.  Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?

Authors:  G Reid; K Anukam; T Koyama
Journal:  Can J Gastroenterol       Date:  2008-02       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.